News >

Strategies Evolve for Overcoming EGFR-TKI Resistance in NSCLC

Caroline Seymour
Published: Thursday, May 16, 2019

Lyudmila A. Bazhenova, MD
Lyudmila A. Bazhenova, MD
Pending overall survival (OS) data from the phase III FLAURA trial, osimertinib (Tagrisso) may be the preferred frontline treatment for patients with EGFR-mutant non–small cell lung cancer (NSCLC), said Lyudmila A. Bazhenova, MD. However, treatment beyond progression on the agent will require more consideration, especially in the face of heterogenous resistance mechanisms.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 22nd Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas and MyelomaMay 30, 20192.0
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Publication Bottom Border
Border Publication
x